Pharma Firm Pfizer unveils Advanced Cancer Medicines at ASCO Meet

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held in Chicago from May 30 to June 3, Pfizer will present data from its entire range of potentially ground-breaking cancer medications. Pfizer's primary tumor areas, including breast, genitourinary, hematologic, and thoracic cancers, as well as colorectal cancer, will be covered by data from over 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including nine oral presentations and six rapid oral presentations.

ASCO's embargoed pre-meeting press briefing on May 27 will include two late-breaking oral presentations from Pfizer. Additional updates from important late-stage programs will be provided by Pfizer, such as the first combination data for ELREXFIO (elranatamab) + daratumumab + lenalidomide from the ongoing MagnetisMM-6 study in patients with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM) and the five-year survival data from the Phase 3 ARCHES study of XTANDI (enzalutamide) in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer (mHPSC).

 “Our data at ASCO this year reflect how we are strategically progressing our deep pipeline of next generation cancer medicines while simultaneously extending the impact of our foundational therapies to reach more people living with cancer. Important early-stage updates highlight our extensive pipeline and depth within our core cancer types, as we advance up to nine new pivotal Phase 3 trials this year”, said Megan O’Meara, Head of Early-Stage Development and Interim Head of Late-Stage Development, Pfizer Oncology.

“This has already been a significant year for Pfizer’s Oncology pipeline, with multiple Phase 3 data readouts and regulatory approvals, and the initiation of pivotal registrational programs across our major tumor areas of focus. The depth and diversity of our data presentations at ASCO are building on that momentum to bring us closer to our goal of delivering eight breakthrough cancer medicines by 2030”, - said Chris Boshoff, MD, PhD, Chief Scientific Officer and President, Research & Development, Pfizer.